Illumina BeadArray Analysis The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array ...

Illumina’s first quarter 2025 results were in line. Revenue and EPS were $1.04 billion and $0.97 (non-GAAP), respectively. No real surprise there. The news was in Illumina’s updated guidance.

In February, Illumina announced it would be laying off 96 San Diego workers. The company, in a statement provided to the Union-Tribune, explained the action as part of an ongoing $100 million cost ...

Illumina has seen a significant decline in its stock price since August 09, 2021. On that day, its stock price was $517.32 and declined to $84.79 on March 20, 2025, representing a sharp drop of 83 ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines.

Illumina’s stock was trading at $131 per share at the start of the year. But since China placed it on the unreliable list last month, the stock has declined about 31%.

Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale ...

Illumina thinks that its combination of breadth of coverage and high resolution is unique and will lead to broad adoption. Early access starts later this year with a full commercial launch ...

Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $150.93, representing a 7.81% upside. In a report released today, Piper Sandler also maintained a Buy rating on ...

Shares of Illumina were down 0.7% at $105.75 as of about 11 a.m. ET Friday. They have lost about three-quarters of their value since the GRAIL purchase, and remain more than 20% lower year-to-date.